Jiong-ping Lu

Array ( [id] => 13729437 [patent_doc_number] => 20180369186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 16/060445 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16060445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649145 [patent_doc_number] => 20170145046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => '6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY' [patent_app_type] => utility [patent_app_number] => 15/366684 [patent_app_country] => US [patent_app_date] => 2016-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 26088 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15366684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11647935 [patent_doc_number] => 20170143836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'UNIQUE DUAL-ACTION THERAPEUTICS' [patent_app_type] => utility [patent_app_number] => 15/365088 [patent_app_country] => US [patent_app_date] => 2016-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15852 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15365088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13548593 [patent_doc_number] => 20180325844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS [patent_app_type] => utility [patent_app_number] => 15/776880 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11588415 [patent_doc_number] => 20170112827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'Morphinan Derivatives with High Oral Bioavailability' [patent_app_type] => utility [patent_app_number] => 15/354244 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5564 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15354244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11942113 [patent_doc_number] => 20170246265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'PHARMACEUTICAL PREPARATIONS FOR ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND OTHER ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/354940 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 4708 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15354940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13461593 [patent_doc_number] => 20180282339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => PROCESS FOR THE PREPARATION OF THE AMORPHOUS FORM OF IBRUTINIB AND NOVEL CRYSTALLINE FORM [patent_app_type] => utility [patent_app_number] => 15/772140 [patent_app_country] => US [patent_app_date] => 2016-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3302 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15772140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13548755 [patent_doc_number] => 20180325925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROINFLAMMATORY DISEASE, CONTAINING PROTEIN TYROSINE PHOSPHATASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 15/773928 [patent_app_country] => US [patent_app_date] => 2016-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15773928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11647779 [patent_doc_number] => 20170143681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATING PAIN' [patent_app_type] => utility [patent_app_number] => 15/341700 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 18599 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15341700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504501 [patent_doc_number] => 20180303793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING TRAUMATIC BRAIN INJURY [patent_app_type] => utility [patent_app_number] => 15/767706 [patent_app_country] => US [patent_app_date] => 2016-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13489957 [patent_doc_number] => 20180296521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL INFLAMMATION [patent_app_type] => utility [patent_app_number] => 15/767747 [patent_app_country] => US [patent_app_date] => 2016-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3267 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14338695 [patent_doc_number] => 20190151320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => APPLICATION OF MAPK SIGNALING PATHWAY INHIBITOR IN MANUFACTURE OF DRUGS FOR DELAYING DEGENERATION OF DOPAMINERGIC NEURONS [patent_app_type] => utility [patent_app_number] => 16/091438 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16091438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368751 [patent_doc_number] => 20180235916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => ENHANCING BETA CELL REPLICATION AND/OR SURVIVAL [patent_app_type] => utility [patent_app_number] => 15/761795 [patent_app_country] => US [patent_app_date] => 2016-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -101 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15761795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13324483 [patent_doc_number] => 20180213779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULPHUR CONTAINING SUBSTITUENTS [patent_app_type] => utility [patent_app_number] => 15/762998 [patent_app_country] => US [patent_app_date] => 2016-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 767 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13925857 [patent_doc_number] => 20190046444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => A STERICALLY STABILIZED CARRIER FOR SUBCUTANEOUS, SUBLINGUAL, AND ORAL THERAPEUTICS, COMPOSITIONS AND METHODS FOR TREATING A MAMMAL [patent_app_type] => utility [patent_app_number] => 15/759651 [patent_app_country] => US [patent_app_date] => 2016-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -143 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15759651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13382093 [patent_doc_number] => 20180242588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => BIOCIDAL MIXTURES [patent_app_type] => utility [patent_app_number] => 15/754073 [patent_app_country] => US [patent_app_date] => 2016-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15754073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982303 [patent_doc_number] => 20190060309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => MDM2 INHIBITORS AND COMBINATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 15/756094 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19852 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15756094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383525 [patent_doc_number] => 20180243304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER [patent_app_type] => utility [patent_app_number] => 15/753045 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7676 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15753045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368743 [patent_doc_number] => 20180235912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES COMPRISING THIOUREA DERIVATIVE [patent_app_type] => utility [patent_app_number] => 15/752079 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15752079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368841 [patent_doc_number] => 20180235961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 [patent_app_type] => utility [patent_app_number] => 15/752130 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22375 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15752130 [rel_patent_id] =>[rel_patent_doc_number] =>)